Figure 6.
Total thrombus formation of patients with NSTEMI treated with ticagrelor in the presence or absence of VLD rivaroxaban. (A) Representative tracings and (B) arithmetic means ± SEM (n = 12) of occlusion start time (T10), AUC and OT of total thrombus formation on a collagen and tissue factor coated (AR) chip in recalcified citrated whole blood from patients with NSTEMI before (baseline) and after medication with ticagrelor + ASA for 1 and 2 days (d1 and d2) in the absence (DMSO) or presence of 40 ng/mL rivaroxaban (in vitro). #P < .05 indicates significant differences from baseline.